IPF Partners

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel treatments for medical conditions with significant unmet needs. The company has a diverse pipeline that addresses acute trauma, cancer, and inflammatory diseases. Its lead product, Traumakine, is an investigational intravenous formulation of interferon beta-1a, currently undergoing Phase III clinical trials for treating acute respiratory distress syndrome (ARDS). Another key candidate, Clevegen, is an immunotherapy designed to prevent tumor growth and metastasis by targeting immune suppressor molecules in tumors, and is in Phase I/II development. Additionally, Faron is developing D-ARDS, a diagnostic tool aimed at assessing ARDS severity and monitoring outcomes. The company collaborates with the MediCity unit of Turku University Medical School to enhance its research and development efforts. Founded in 2003, Faron Pharmaceuticals is committed to advancing innovative solutions in healthcare.

Patient21 operates a health platform focused on improving the doctor-patient connection, which they view as essential for effective healthcare. The company aims to modernize the healthcare experience by addressing the fragmented and outdated processes currently prevalent in the industry. By leveraging technology, Patient21 enhances dental clinics with management software that streamlines administrative tasks such as appointment scheduling and patient data management. They also provide electronic health records (EHR) to healthcare professionals, which helps improve diagnostic quality and reduce costs. Through these innovations, Patient21 seeks to facilitate better decision-making for both patients and physicians, ultimately promoting a more personalized and collaborative approach to healthcare.

Poxel is a biopharmaceutical company based in Lyon, France, focused on developing innovative drugs for metabolic diseases, with a primary emphasis on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009, Poxel's lead product is Imeglimin, an oral anti-diabetic candidate in Phase III clinical development that targets key organs affected by diabetes, such as the pancreas, liver, and muscles. The company is also advancing PXL770, an adenosine monophosphate-activated protein kinase enzyme in Phase IIa clinical trials for treating chronic metabolic diseases like NASH. Additionally, Poxel has licensing agreements for PXL007 (EYP001), an FXR agonist in Phase I study for hepatitis B and NASH, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I clinical trials for NASH.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel treatments for medical conditions with significant unmet needs. The company has a diverse pipeline that addresses acute trauma, cancer, and inflammatory diseases. Its lead product, Traumakine, is an investigational intravenous formulation of interferon beta-1a, currently undergoing Phase III clinical trials for treating acute respiratory distress syndrome (ARDS). Another key candidate, Clevegen, is an immunotherapy designed to prevent tumor growth and metastasis by targeting immune suppressor molecules in tumors, and is in Phase I/II development. Additionally, Faron is developing D-ARDS, a diagnostic tool aimed at assessing ARDS severity and monitoring outcomes. The company collaborates with the MediCity unit of Turku University Medical School to enhance its research and development efforts. Founded in 2003, Faron Pharmaceuticals is committed to advancing innovative solutions in healthcare.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries, utilizing its proprietary Dynamic Surgical Guidance (DSG®) technology. This powerful, radiation-free sensing platform enhances the accuracy and safety of skeletal implant placement through real-time audio and visual feedback for surgeons. The company's flagship product, the PediGuard probe, is specifically designed for spine surgery, allowing surgeons to create pilot holes in vertebrae with precision. Equipped with a sensor that measures electrical conductivity, the PediGuard alerts surgeons to changes in bone and tissue types without the need for X-ray imaging. Available in various shapes and sizes, these devices cater to a wide range of surgical needs, from pediatric deformity corrections to adult degenerative conditions. With over 80,000 successful spinal procedures supported by PediGuard and substantial clinical evidence backing its efficacy, SpineGuard aims to address critical challenges in pedicle screw placement while improving patient outcomes and operational efficiency in the surgical environment.

Genesis Automation specializes in innovative healthcare solutions that enhance patient safety and operational efficiency within healthcare organizations. The company has developed a clinical traceability platform that tracks the movement of critical supplies and equipment throughout the healthcare supply chain, from manufacturers to points of care. This suite of tools enables hospitals and suppliers to ensure that patients receive the correct medications and devices, ultimately reducing costs and eliminating waste in the healthcare system. By focusing on improving the value-chain processes, Genesis Automation aims to create a safer and more efficient healthcare environment for both providers and patients.

Genesis Automation is a single source, full-service automated system solutions provider. It designs and builds high-precision assembly, test, and special process equipment for a wide range of industries. Genesis Automation was founded in 1999 and is based in Cork, Ireland.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Mauna Kea Technologies SA is a medical device company headquartered in Paris, France, specializing in the development and marketing of advanced imaging technology for the diagnosis and treatment of cancers and other diseases. Founded in 2000, the company focuses on real-time in vivo microscopic visualization to eliminate uncertainties in medical diagnoses. Its primary product, Cellvizio, is a multidisciplinary confocal laser endomicroscopy platform that enables physicians to obtain cellular-level images of tissues during standard medical procedures. Cellvizio has received regulatory approval for use in the United States and over 40 other countries, supporting a wide range of applications. Mauna Kea Technologies generates revenue through the sale of Cellvizio devices, accessories, and related services, while emphasizing its role in enhancing diagnostic accuracy and informing therapeutic decisions.

Impeto Medical SAS is a privately owned medical device company established in June 2005, with its headquarters located in Paris, France, and additional subsidiaries in China and San Diego, California. The company specializes in the manufacture and marketing of non-invasive diagnostic devices that assess eccrine sweat gland activity. Its product lineup includes SUDOSCAN+, which is used for detecting and monitoring peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardio metabolic risks; and SUDOSCAN, a device that evaluates galvanic skin response to assess sympathetic nervous system behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical's innovative technology enables healthcare professionals to screen large patient populations effectively, facilitating early detection of metabolic disorders and related complications. The company distributes its products through a network of distributors.

Neuravi Limited, established in 2009 and based in Galway, Ireland, specializes in designing and developing medical devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries and is a subsidiary of DePuy Ireland Unlimited Company.

i-Optics, established in 2006, is a Dutch medical device company specializing in corneal diagnostic solutions. It offers the Cassini Corneal Shape Analyzer, a pioneering tool using color LED technology to precisely measure corneal astigmatism, enhancing premium IOL planning. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system for diagnosing various eye diseases. Their suite of examinations, including corneal topography, pupillometry, and full-color photography, empowers cataract surgeons to better understand corneal properties, improving surgical outcomes and increasing patient satisfaction.

Genesis Automation specializes in innovative healthcare solutions that enhance patient safety and operational efficiency within healthcare organizations. The company has developed a clinical traceability platform that tracks the movement of critical supplies and equipment throughout the healthcare supply chain, from manufacturers to points of care. This suite of tools enables hospitals and suppliers to ensure that patients receive the correct medications and devices, ultimately reducing costs and eliminating waste in the healthcare system. By focusing on improving the value-chain processes, Genesis Automation aims to create a safer and more efficient healthcare environment for both providers and patients.

SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries, utilizing its proprietary Dynamic Surgical Guidance (DSG®) technology. This powerful, radiation-free sensing platform enhances the accuracy and safety of skeletal implant placement through real-time audio and visual feedback for surgeons. The company's flagship product, the PediGuard probe, is specifically designed for spine surgery, allowing surgeons to create pilot holes in vertebrae with precision. Equipped with a sensor that measures electrical conductivity, the PediGuard alerts surgeons to changes in bone and tissue types without the need for X-ray imaging. Available in various shapes and sizes, these devices cater to a wide range of surgical needs, from pediatric deformity corrections to adult degenerative conditions. With over 80,000 successful spinal procedures supported by PediGuard and substantial clinical evidence backing its efficacy, SpineGuard aims to address critical challenges in pedicle screw placement while improving patient outcomes and operational efficiency in the surgical environment.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with additional operations in the United States and Australia. The company specializes in developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant underserved population. Mainstay Medical has created an FDA-approved restorative treatment designed to enhance muscle control and improve functionality in the lumbar spine. This therapy aims to help patients regain mobility and enhance their overall quality of life. By collaborating with scientists and clinical experts, Mainstay Medical is committed to advancing solutions for those affected by debilitating back pain.

i-Optics, established in 2006, is a Dutch medical device company specializing in corneal diagnostic solutions. It offers the Cassini Corneal Shape Analyzer, a pioneering tool using color LED technology to precisely measure corneal astigmatism, enhancing premium IOL planning. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system for diagnosing various eye diseases. Their suite of examinations, including corneal topography, pupillometry, and full-color photography, empowers cataract surgeons to better understand corneal properties, improving surgical outcomes and increasing patient satisfaction.

EOS Imaging SA is a medical technology company based in Paris, France, specializing in low-dose 2D/3D imaging and software solutions for osteo-articular conditions and orthopedic surgeries. The company develops and markets the EOS imaging system, which produces full-body, stereo-radiographic images of patients in functional positions, tailored to the specific needs of orthopedic surgeons and radiologists. Its product offerings include EOSedge, a high-quality X-ray system, sterEOS, a 3D modeling workstation for precise skeletal analysis, and EOSapps, online surgical planning solutions based on real-time imaging. Additionally, EOS Imaging creates planning software for knee and hip surgeries and manufactures patient-specific cutting guides for orthopedic procedures. The company operates globally, with a presence in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America, and has obtained marketing authorization for its systems in 48 countries. Founded in 1989, EOS Imaging was previously known as biospace med before rebranding in 2010.

Mendor is a Finnish company focused on the design, development, and marketing of advanced diabetes management products. It has introduced an innovative all-in-one blood glucose meter and a web-based software application that simplify daily diabetes management. These products are developed in collaboration with users and diabetes experts, ensuring they meet the specific needs of individuals requiring regular blood glucose monitoring. Mendor's patented software systems deliver real-time diabetes care data, enhancing the efficiency and effectiveness of treatment for patients and caregivers alike.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.